Editors' Consensus Report The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease r

Acknowledgment:This Editors’ Consensus is sup-ported by an educational grant from Colgate-Palmo-live, Inc., New York, New York, and is based on ameetingoftheauthorsheldinBoston,Massachusetts,on January 9, 2009.Disclosure: Dr. Friedewald has received honor-aria for speaking from Novartis, East Hanover, NewJersey. Dr. Kornman is a full-time employee andshareholder of Interleukin Genetics, Waltham, Massa-chusetts, which owns patents on genetic biomarkersfor chronic inflammatory diseases. Dr. Genco is a con-sultant to Merck, Whitehouse Station, New Jersey.Dr. Ridker has received research support fromAstraZeneca, Wilmington, Delaware; Novartis; Pfizer,New York, New York; Roche, Nutley, New Jersey;Sanofi-Aventis, Bridgewater, New Jersey; and AbbottLaboratories, Abbott Park, Illinois. Dr. Ridker has re-ceived non-financial research support from Amgen,Thousand Oaks, California. Dr. Ridker is a co-inventoronpatentsheldbyBrighamandWomen’sHospitalthat relate to the use of inflammatory biomarkers incardiovasculardisease.Dr.Ridkerisaresearchconsul-tant for Schering-Plough, Kenilworth, New Jersey;Sanofi-Aventis; AstraZeneca; Isis, Carlsbad, California;Novartis; and Vascular Biogenics, Tel Aviv, Israel. Dr.Van Dyke is a co-inventor on patents held by BostonUniversity, Boston, Massachusetts, that relate to in-flammation control, including consulting fees. Dr.Roberts has received honoraria for speaking fromMerck, Schering-Plough, AstraZeneca, and Novartis.All other individuals in a position to control contentdisclosed no relevant financial relationships. JPeri-odontol 2009;80:1021-1032.